Fig. 2.

AWARD 7 trial: Composite kidney outcome of ≥40% decline in estimated glomerular filtration rate (eGFR) or end-stage kidney disease (ESKD) with dulaglutide 0.75 or 1.5 mg/wk vs insulin glargine. Panel A: Proportion experiencing primary outcome by treatment group. Panel B: Time to first event for primary outcome by treatment group. Used with permission of American Society of Nephrology, from Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis, Kidney360, Tuttle KR, et al., 2, 2 © 2021; permission conveyed through Copyright Clearance Center, Inc.